Overview of US Patent 8,980,319
US Patent 8,980,319, granted on February 17, 2015, primarily covers a novel pharmaceutical composition and methods related to its use. The patent’s scope focuses on a specific chemical compound with therapeutic applications, particularly in oncology. The patent claims emphasize the compound's structural features, formulations, and therapeutic methods.
Scope of the Patent Claims
Claims Breakdown:
-
Chemical Structure and Composition: The core claims protect a specific class of compounds characterized by a defined chemical scaffold. These structures include substituted heteroaryl and aryl groups attached to a central core, targeting kinase inhibition.
-
Method of Use: Claims include methods of treating cancer by administering the compound. The claims specify doses, administration routes, and treatment durations.
-
Pharmaceutical Formulation: The patent covers compositions including the compound combined with pharmaceutically acceptable carriers and excipients.
-
Prodrug and Isomer Variants: Claims extend to prodrug forms and stereoisomeric variants of the active compound.
Scope Analysis:
The patent's claims are relatively broad within the scope of kinase inhibitors targeting specific signaling pathways implicated in tumor growth. The composition and method claims are designed to cover the compound's application in cancer therapy, with specific focus on lung and breast cancers.
Specific Claim Features:
-
Claim 1: A compound of a particular formula with specific substituents, defining the chemical space targeted.
-
Claims 2-10: Dependent claims expand on variations, including different substituents, salt forms, and derivatives.
-
Claims 11-15: Cover methods of treating cancers using the compound, with specific dosing regimens.
Claimed compounds are structurally related to known kinase inhibitors like Erlotinib or Gefitinib but with distinct substitutions.
Patent Landscape Overview
Key Patent Families and Related Patents:
-
Originating Patent: The ‘319 patent is part of a larger patent family developed by Array BioPharma (now part of Pfizer). It belongs to a cluster of patents targeting kinase inhibitors with similar structures.
-
Competitor Patentings: Several patents by Teva, Novartis, and other pharmaceutical firms cover similar compounds, often overlapping in the kinase inhibition class.
-
Blockbuster Patent Influence: The ‘319 patent builds on prior art, including U.S. patents such as 7,857,879 and 8,515,245, which cover earlier generations of kinase inhibitors.
Patent Status and Lifecycle:
-
Expiration Date: Patent rights expire in 2032, considering patent term adjustments for regulatory delays.
-
Generics and Biosimilar Pathways: The broad claims on the compound's chemical structure may impede generic entry until expiration, but narrow claims on specific uses may have limited enforceability against off-label applications.
-
International Patent Landscape: Similar compounds are protected via patent families filed internationally, notably in Europe (EP patents), Japan (JP patents), and China (CN patents).
Legal and Enforcement Considerations
-
Potential Patent Challenges: The scope may face challenges based on obviousness, especially given prior art around kinase inhibitors. Patentability could be questioned for specific compounds with known motifs.
-
Litigation History: No publicly available litigation records directly involving the patent have been reported, but infringement suits are common in drug patent landscapes, particularly with broad claims.
-
Standing and Patent Ownership: The patent has been assigned to Array BioPharma at issuance, with subsequent transfers to Pfizer after acquisition.
Research and Development Context
The patent supports ongoing R&D for kinase inhibitors in oncology. Its claims potentially lock in a chemical class relevant for combination therapies, such as with immunotherapies or chemo agents.
Key Takeaways
-
Broad Chemical Scope: The claims cover specific kinase-inhibitor structures with potential for broad therapeutic use in oncology.
-
Method and Composition Claims: The patent includes both composition claims (chemical compounds) and method claims (treatment regimes).
-
Patent Family and Landscape: It is part of a patent family with multiple filings and overlaps with prior art, limiting the scope against future inventions within similar chemical classes.
-
Potential for Patent Challenges: The patent’s breadth, especially on structural claims, could be vulnerable to patent invalidation if prior art is found.
-
Market Implication: Patent protection provides exclusivity until 2032, allowing Pfizer or licensees to market the drug following regulatory approval.
FAQs
Q1: What specific chemical structures are protected by US Patent 8,980,319?
It protects compounds with a defined heteroaryl or aryl substitution pattern attached to a central core, designed as kinase inhibitors targeting cancer pathways.
Q2: Does the patent cover all kinase inhibitors in its class?
No. It claims specific structures and their derivatives, not all kinase inhibitors broadly, although it overlaps with related classes.
Q3: Can the claims be challenged based on prior art?
Potentially. The chemical class overlaps with previously known kinase inhibitors, which may be grounds for patent invalidation if prior art is sufficiently similar and renders the claims obvious.
Q4: Are method-of-use claims enforceable if the compound is used off-label?
Method claims are enforceable against designated methods of treatment. Off-label uses are generally not covered unless explicitly claimed.
Q5: How does the patent landscape affect generic development?
The structure-based claims will delay generic entry until patent expiration in 2032 unless challenges succeed or narrow claims are invalidated.
References
[1] US Patent 8,980,319.
[2] Patent Family Databases and PatentScope.
[3] FDA Approval documents.
[4] Patent Challenge and Litigation Reports in Oncology.
